Dr. Elisabeth Buchdunger - CML - Chronic myeloid leukemia

''Dr. Elisabeth Buchdunger of Novartis Pharma AG, Switzerland received her PhD in Biology from the University of Freiburg, Germany. Following postdoctoral positions at the Friedrich-Miescher Institute, Basel, and the University of Basel, she joined the Oncology Research group at Ciba-Geigy (now Novartis) in 1990. Working in the signal transduction field, she established cellular assays for the identification and characterization of protein kinase inhibitors. She contributed to the development of several protein kinase inhibitors, including Glivec. She is the preclinical research representative in the International Project Team for Glivec and has gained a practical understanding of both Research & Development aspects at the pharmaceutical process. She is one of the recipients of the Bruce-Cain Memorial Award (2002) from the American Association for Cancer Research (AACR).''
Extract of  http://www.biofinland.fi/2003/biographies.htm
PUBLICATIONS

Druker,D., Talpaz,M., Resta, R.N., Peng, B., Buchdunger, E., Ford, J., Lydon, N.B., Kantarjian, H., Capdeville, R., Jones-Ohno, Sand Sawyers, C.L. Clinical Efficacy and Safety of an Abl Specific tyrosine kinase inhibitor as a targeted therapy for chronic myeloid leukaemia. N. Engl J. Med. 2001, 344, 1031-1037.

Elisabeth Buchdunger, Catherine L. Cioffi, Norman Law, David Stover, Sayuri Ohno-Jones, Brian J. Druker and Nicholas B. Lydon. The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J.Pharmacol. Exp. Ther. 2000, Oct; 95(1):139-45

Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997 Dec 15;90(12):4947-52

Zimmermann J, Buchdunger, E., Mett H, Meyer T, Lydon NB. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorganic & Medicinal Chemistry Letters, 1997; 187-192

Zimmermann, J., Buchdunger, E., Mett H., Meyer, Th., Lydon, N.B., Traxler, P. Phenylamio-pyrimidine derivatives: a new class of potent and selective PDGF-receptor kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 1996; 6:1221-1226.

Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 1996 Jun 7;39(12):2285-92.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 1996 May;2(5):561-6

Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996 Jan 1;56,100-4.



                                        See also  The CML Experts